SAN
DIEGO, Nov. 18, 2022 /PRNewswire/ -- Inhibrx,
Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company
dedicated to the development of therapeutics for oncology and rare
diseases, today announced it will be presenting at the following
upcoming virtual investor conference:
The Evercore ISI 5th Annual HealthCONx
Conference
Wednesday, November
30th at 8:45 a.m. Pacific
Time
The investor conference presentation will be webcast live for at
least 60 days following the event and will be accessible through a
link on the investors section of Inhibrx's website
at https://inhibrx.investorroom.com/events-and-presentations.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biopharmaceutical company focused on
developing a broad pipeline of novel biologic therapeutic
candidates in oncology and orphan diseases. Inhibrx utilizes
diverse methods of protein engineering to address the specific
requirements of complex target and disease biology, including its
proprietary sdAb platform. Inhibrx has collaborations with 2seventy
bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi. For
more information, please visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conference-301682619.html
SOURCE Inhibrx Inc.